Form 4: Ventyx Biosciences Executive Exercises Stock Options
SEC Form 4 Filing
Christopher Krueger, Chief Business Officer of Ventyx Biosciences, reports the exercise of stock options and subsequent changes in beneficial ownership.
Summary
- On March 28, 2024, Christopher Krueger, the Chief Business Officer of Ventyx Biosciences, exercised restricted stock units (RSUs) resulting in the acquisition of 4,531 shares of common stock.
- The exercise price for the RSUs was $0.
- Following the transaction, Krueger directly owns 13,594 derivative securities and 286,650 shares of Ventyx Biosciences common stock.
- The RSUs vest 25% annually, starting on the one-year anniversary of March 28, 2023, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard regulatory filing related to insider transactions. It is common for executives to receive and exercise stock options as part of their compensation.
Stakeholder Impact
- The transaction affects the beneficial ownership of Ventyx Biosciences' shares, which is relevant to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/28/2023 | RSU Vesting Commencement Date |
| 03/28/2024 | Date of transaction (exercise of RSUs) |
| 03/29/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.